This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Esophageal adenocarcinoma is a type of cancer that affects the esophagus, the tube connecting the throat to the stomach. It is the most common type of esophageal cancer in the United States. Esophageal adenocarcinoma usually begins in the cells that line the inside of the esophagus. It is often caused by damage to the cells due to chronic acid reflux, in which stomach acid flows backward into the esophagus. Other risk factors for esophageal adenocarcinoma include obesity, smoking, and alcohol consumption. Symptoms of esophageal adenocarcinoma may include difficulty swallowing, pain in the chest or throat, and weight loss. Diagnosis is typically done through endoscopy, in which a doctor inserts a thin tube with a camera into the esophagus to look for cancerous cells. Blood tests, imaging tests, and biopsy may also be used to diagnose the cancer. Treatment for esophageal adenocarcinoma typically involves surgery to remove the tumor, as well as chemotherapy and radiation therapy. The prognosis for esophageal adenocarcinoma depends on the stage of the cancer and the patient’s overall health. Early detection and treatment are important for improving the chance of a successful outcome. Esophageal adenocarcinoma can be a difficult cancer to diagnose and treat, but there are many options available to those who are diagnosed. By understanding the risk factors, recognizing the symptoms, and getting regular check-ups, people can help to reduce their risk of developing esophageal adenocarcinoma.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States